Harmonizing Heterogeneous Endpoints in Coronavirus Disease 2019 Trials Without Loss of Information.

ABSTRACT:

Objectives

Many trials investigate potential effects of treatments for coronavirus disease 2019. To provide sufficient information for all involveddecision-makers (clinicians, public health authorities, and drug regulatory agencies), a multiplicity of endpoints must be considered. The objectives are to provide hands-on statistical guidelines for harmonizing heterogeneous endpoints in coronavirus disease 2019 clinical trials.

Design

Randomized controlled trials for patients infected with coronavirus disease 2019.

Setting

General methods that apply to any randomized controlled trial for patients infected with coronavirus disease 2019.

Patients

Coronavirus disease 2019 positive individuals.

Interventions

None.

Measurements and main results

We develop

SUBMITTER: von Cube M 

PROVIDER: S-EPMC7737851 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature